Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-21
2011-06-21
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S235800, C514S249000, C514S252140, C514S275000, C544S060000, C544S122000, C544S295000, C544S323000
Reexamination Certificate
active
07964592
ABSTRACT:
Novel pyrimidine derivatives of formula Ito process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
REFERENCES:
patent: 3361749 (1968-01-01), Matter et al.
patent: 3432493 (1969-03-01), Short
patent: 5958935 (1999-09-01), Davis et al.
patent: 6048866 (2000-04-01), Hutchings et al.
patent: 6093716 (2000-07-01), Davis et al.
patent: 6114333 (2000-09-01), Davis et al.
patent: 6235746 (2001-05-01), Davis
patent: 6593326 (2003-07-01), Bradbury et al.
patent: 7514446 (2009-04-01), Davis-Ward et al.
patent: 7671063 (2010-03-01), Baenteli et al.
patent: 2006/0100227 (2006-05-01), Baenteli et al.
patent: 2008/0132504 (2008-06-01), Garcia-Echeverria et al.
patent: 1 054 004 (2000-11-01), None
patent: 1 184 376 (2002-03-01), None
patent: 1184376 (2005-02-01), None
patent: 97/19065 (1997-05-01), None
patent: 9841512 (1998-09-01), None
patent: 99/50250 (1999-10-01), None
patent: 99/50250 (1999-10-01), None
patent: 00/12485 (2000-03-01), None
patent: 00/12485 (2000-03-01), None
patent: 00/39101 (2000-07-01), None
patent: 0125220 (2001-04-01), None
patent: 01/60816 (2001-08-01), None
patent: 01/64654 (2001-09-01), None
patent: 01/64655 (2001-09-01), None
patent: 01/64656 (2001-09-01), None
patent: 01/65655 (2001-09-01), None
patent: 02056888 (2002-07-01), None
patent: 03/018021 (2003-03-01), None
patent: 03/030909 (2003-04-01), None
patent: 03/063794 (2003-08-01), None
patent: 03/066601 (2003-08-01), None
patent: 03/066601 (2003-08-01), None
patent: 03/078404 (2003-09-01), None
patent: 03/095448 (2003-11-01), None
patent: 03/095448 (2003-11-01), None
patent: 2004/002964 (2004-01-01), None
patent: 2004056786 (2004-07-01), None
patent: 2004/074244 (2004-09-01), None
patent: 2004/074244 (2004-09-01), None
patent: 2004/080980 (2004-09-01), None
patent: 2004/080980 (2004-09-01), None
patent: 2005/016894 (2005-02-01), None
patent: 2005026130 (2005-03-01), None
patent: 2006068770 (2006-06-01), None
Traxler, Protein Tyrosine Kinase Inhibitors in Cancer Treatment, Expert Opinion on Therapeutic Patents, 7(6):571-588, 1997.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Ghosh et al., “2,4-Bis(Arylamino)-5-methylpyrimidines as antimicrobial agents,” Journal of Medicinal Chemistry, vol. 10, No. 5, p. 974 (1967).
Ghoneim et al., “Synthesis and evaluation of some 2-, 4- and 2, 4-Di-Substituted-6-Methylpyrimidine Derivatives for Antimicrobial Activity,” Journal of the Indian Chemical Society, vol. 63, No. 10, pp. 914-917 (1986).
Ghosh D., “2,4-Bis(arylamino)-6-methylpyrimidines as antimicrobial agents,” Journal of the Indian Chemical Society, vol. 58, No. 5, pp. 512-513 (1981).
van Seventer et al., “Focal Adhesion Kinase Regulates B1, Integrin Dependent T Cell Migration Through an HEF1 Effector Pathway,” Eur. J. Immunol. 31:1417-1427 (2001).
Wood et al., “A Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration,” Cancer Res. 60:2178-2189 (Apr. 15, 2000).
Dirks et al., “Expression and Functional Analysis of the Anaplastic Lymphoma Kinase (ALK) Gene In Tumor Cell Lines,” Int. J. Cancer 100:49-56 (2002).
Traxler, Peter M. , “Protein Tyrosine Kinase Inhibitors in Cancer Treatment”, Expert Opinion on Therapeutic Patents, vol. 7, No. 6, pp. 571-588, 1997.
Simone et al., Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1997.
Basford et al., CAPLUS Abstract 41:763, pp. 7810-7812,1947.
Coopman et al., “The Syk Tyrosine Kinase Suppresses Malignant Growth of Human Breast Cancer Cells”, Nature, vol. 406, pp. 742-747, Aug. 17, 2000.
USPTO Final Office Action mailed Mar. 16, 2010, of pending U.S. Appl. No. 10/568,367 (U.S. Patent Publication No. 2008/0132504).
Garcia-Echeverria Carlos
Kanazawa Takanori
Kawahara Eiji
Masuya Keiichi
Matsuura Naoko
Genomics Institute of the Novartis Research Foundation
Novartis AG
Rao Deepak
Tongco Wu Emily
LandOfFree
2,4-di (phenylamino) pyrimidines useful in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,4-di (phenylamino) pyrimidines useful in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4-di (phenylamino) pyrimidines useful in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623435